Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 26, 2019Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020,...
Aug 21, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells...
Aug 6, 2019- As reported, revenues of $4.350 billion increased 1.7 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019....
-
Jul 23, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and...
-
Jul 22, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on...
-
Jul 18, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100...
-
Jul 2, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m....
-
Jun 20, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory...
-
Jun 4, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the...
-
Jun 4, 2019Findings Based on Survey of 650 Health Care Professionals
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in...
-
Jun 3, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority...
-
May 31, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on...
-
May 20, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the...
-
May 9, 2019- As reported, revenues of $4.195 billion decreased 0.6 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for the second fiscal quarter ended March 31, 2019....
Apr 30, 2019New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™...
Apr 8, 2019BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global availability of BD BACTEC™ platelet quality control media, which allows...
Mar 26, 2019BD FACSDuet(TM) system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric(TM) clinical flow cytometerBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet(TM) automated flow cytometry system. The...
-
Mar 21, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers...
Mar 14, 2019Venovo(TM) Venous Stent proven safe and effective in iliac and femoral veinsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo(TM)...
-
Feb 13, 2019BD WavelinQ™ 4F EndoAVF System Receives 510(k) Clearance from U.S. Food and Drug Administration
FRANKLIN LAKES, N.J., February 13, 2019 –BD (Becton, Dickinson and Company), a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration for...
-
Feb 5, 2019- As reported, revenues of $4.160 billion increased 35.1 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31,...
-
Jan 24, 2019BD Nano(TM) Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the U.S. Food and Drug Administration 510(k) clearance of its second generation BD Nano(TM)...
-
Dec 20, 2018BD MAX(TM) Enteric Viral Panel Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX(TM) enteric viral...
Dec 11, 2018BD FACSLyric(TM) Flow Cytometer is First BD Product to Earn UL Cybersecurity Assurance Program CertificationBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This...
-
Nov 29, 2018Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems...